Cytokinetics (CYTK) Competitors

Cytokinetics logo
$46.16 +4.54 (+10.91%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$46.25 +0.09 (+0.19%)
As of 02/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CYTK vs. TEVA, BGNE, SMMT, ITCI, VTRS, GMAB, MRNA, RDY, SRPT, and PCVX

Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Cytokinetics vs.

Teva Pharmaceutical Industries (NYSE:TEVA) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 3.4% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries currently has a consensus price target of $23.57, indicating a potential upside of 45.19%. Cytokinetics has a consensus price target of $82.00, indicating a potential upside of 77.64%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Cytokinetics
0 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.94

Teva Pharmaceutical Industries received 515 more outperform votes than Cytokinetics when rated by MarketBeat users. However, 79.92% of users gave Cytokinetics an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.

CompanyUnderperformOutperform
Teva Pharmaceutical IndustriesOutperform Votes
1331
67.87%
Underperform Votes
630
32.13%
CytokineticsOutperform Votes
816
79.92%
Underperform Votes
205
20.08%

Teva Pharmaceutical Industries has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Teva Pharmaceutical Industries has a net margin of -9.91% compared to Cytokinetics' net margin of -17,906.25%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-9.91% 42.46% 6.65%
Cytokinetics -17,906.25%N/A -50.21%

In the previous week, Cytokinetics had 7 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 21 mentions for Cytokinetics and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.79 beat Cytokinetics' score of 0.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
2 Very Positive mention(s)
0 Positive mention(s)
12 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Neutral

Cytokinetics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.54B1.11-$1.64B-$1.45-11.20
Cytokinetics$3.22M1,692.30-$526.24M-$5.38-8.58

Summary

Cytokinetics beats Teva Pharmaceutical Industries on 11 of the 19 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTK vs. The Competition

MetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.45B$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%3.99%
P/E Ratio-8.589.6826.1919.41
Price / Sales1,692.30317.72464.8976.77
Price / CashN/A75.4646.1438.90
Price / Book-11.725.537.285.05
Net Income-$526.24M$123.46M$3.19B$222.81M
7 Day Performance9.36%1.37%1.68%1.29%
1 Month Performance0.92%2.09%4.10%1.52%
1 Year Performance-39.97%1.28%22.06%16.53%

Cytokinetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTK
Cytokinetics
4.4052 of 5 stars
$46.16
+10.9%
$82.00
+77.6%
-40.0%$5.45B$3.22M-8.58250High Trading Volume
TEVA
Teva Pharmaceutical Industries
3.0166 of 5 stars
$16.82
-0.1%
$23.57
+40.2%
+24.7%$19.05B$16.54B-11.6037,851Short Interest ↑
BGNE
BeiGene
1.759 of 5 stars
N/A$253.69
+∞
N/A$18.03B$3.32B-22.429,000
SMMT
Summit Therapeutics
2.6207 of 5 stars
$20.50
+1.9%
$33.57
+63.8%
+321.5%$15.12B$700,000.00-73.21110
ITCI
Intra-Cellular Therapies
4.0172 of 5 stars
$127.12
+0.1%
$103.62
-18.5%
+69.0%$13.52B$612.78M-146.11560Analyst Forecast
Short Interest ↑
VTRS
Viatris
3.3601 of 5 stars
$10.62
-1.0%
$13.67
+28.7%
-17.3%$12.68B$15.43B-14.3538,000
GMAB
Genmab A/S
4.7976 of 5 stars
$18.69
-1.6%
$45.20
+141.8%
-25.8%$12.37B$2.39B18.152,204Earnings Report
Short Interest ↓
Analyst Revision
MRNA
Moderna
4.8388 of 5 stars
$31.87
-2.2%
$67.26
+111.1%
-62.7%$12.26B$6.85B-5.485,600Gap Down
RDY
Dr. Reddy's Laboratories
2.9941 of 5 stars
$13.83
-0.5%
$17.00
+23.0%
-10.0%$11.54B$3.35B22.0127,048Short Interest ↑
Analyst Revision
Gap Down
SRPT
Sarepta Therapeutics
4.5304 of 5 stars
$112.74
+0.8%
$178.71
+58.5%
-19.8%$10.77B$1.24B90.191,314
PCVX
Vaxcyte
2.7194 of 5 stars
$85.94
-1.7%
$145.71
+69.6%
+11.6%$10.71BN/A-18.68160Positive News

Related Companies and Tools


This page (NASDAQ:CYTK) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners